A pill version of GLP-1 drugs just matched a standard diabetes drug

The past few weeks brought a mix of encouraging research and necessary warnings for anyone following GLP-1 drugs. A new oral option showed it can hold its own against an established diabetes medication, while FDA warning letters dated September 23 and 24 went to two online sellers of unapproved semaglutide. Together, these updates point to the same lesson: real progress on GLP-1 treatments is happening through legitimate trials and approved channels, not through unregulated online sellers. That distinction matters if you're considering any GLP-1 medication for yourself or a family member.

People with obesity and advanced kidney disease often face an added hurdle: many transplant programs set weight-related criteria before they will add someone to the transplant list. The upcoming phase 4 trial in Canada will examine whether semaglutide, combined with virtual coaching, can help patients meet those criteria and move toward transplantation. Enrollment of 880 participants is set to begin in January 2027, which means results will not be available for some time. For patients and families hoping to get on a transplant list, this trial signals that researchers are looking specifically at how GLP-1 drugs might support this group, though no conclusions can be drawn until the study is complete.

The FDA's warning letter to Cheap Medicine Shop, dated September 24, addresses a problem that has become familiar: online sellers offering semaglutide without the approvals that ensure a drug's safety and quality. The letter names one product sold as Semanext Injection. Unlike pharmacies that operate within FDA oversight, these unlicensed sellers aren't required to prove their products contain the correct ingredients in the correct amounts. That gap creates real risk, since buyers have no way to confirm whether what they receive is counterfeit or contaminated. Anyone considering a GLP-1 medication should treat the source of that medication as seriously as the decision to take it at all.

A second warning letter, dated September 23, went to Online Generic Medicine for selling unapproved and misbranded semaglutide sold as Semanat Injection, a name that does not belong to any FDA-approved product. An unfamiliar brand name like this can make a product look legitimate to someone searching for a known medication. The FDA said unapproved semaglutide products like these carry risks because the agency has not reviewed them for safety, quality or effectiveness. The two letters, sent a day apart, suggest the FDA is actively tracking multiple sellers rather than responding to a single isolated case. A warning letter is a formal notice, not a shutdown; the FDA can take further action if a seller does not fix the problems. Patients who have purchased semaglutide online, particularly from unfamiliar brands, may want to check whether that seller has appeared in an FDA warning before continuing to use the product.

The phase 3 trial results for safiglipron offer a different kind of update, focused on expanding treatment options rather than policing bad actors. In this study, the oral pill performed as well as dapagliflozin, an established type 2 diabetes drug, for patients whose blood sugar wasn't adequately controlled by metformin alone. Because safiglipron is taken as a pill rather than injected, a result like this could matter for patients who prefer or need an oral option. The study was randomized, double-blind, and compared directly against an active treatment rather than a placebo, which strengthens confidence in the comparison.

If you're exploring GLP-1 treatment, the clearest takeaway from these updates is to rely on two things: your prescribing physician and FDA-approved sources for the medication itself. Research into new formulations and new patient groups continues to move forward through proper trials, and that progress is worth watching. But none of it changes the risk posed by unlicensed online sellers, who remain a separate and ongoing problem. Staying informed about both tracks, the legitimate research and the regulatory warnings, will serve you better than following either one alone.

By Amanda Bonello